GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » DeferredTaxAndRevenue

BCAL Diagnostics (ASX:BDX) DeferredTaxAndRevenue : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

BCAL Diagnostics's current deferred tax and revenue for the quarter that ended in Dec. 2023 was A$0.00 Mil.

BCAL Diagnostics DeferredTaxAndRevenue Historical Data

The historical data trend for BCAL Diagnostics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics DeferredTaxAndRevenue Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23
DeferredTaxAndRevenue
- -

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
DeferredTaxAndRevenue Get a 7-Day Free Trial - - - - -

BCAL Diagnostics DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


BCAL Diagnostics (ASX:BDX) Business Description

Traded in Other Exchanges
N/A
Address
Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.